WuXi AppTec acquires Oxgene, adding to its CGT capabilities

By The Science Advisory Board staff writers

March 2, 2021 -- WuXi AppTec has completed the acquisition of Oxgene, a U.K.-based contract research and development organization that designs and develops scalable gene therapy technologies. The acquisition will allow WuXi to provide its customers with end-to-end support in the creation and development of cell and gene therapies (CGT), according to the company.

Oxgene will become a fully owned subsidiary of WuXi Advanced Therapies, the company's cell and gene therapy contract testing, development, and manufacturing organization business unit. Oxgene will retain its name and become WuXi Advanced Therapies' first facility in Europe.

In addition to providing contract research solutions, Oxgene also provides scalable manufacturing systems that simplify cell and gene manufacturing while reducing costs of production. These technologies include its novel tetracycline enabled self-silencing adenovirus (TESSA) technology for adeno-associated viral (AAV) manufacturing and XLenti stable solutions for lentiviral manufacturing.

WuXi Biologics opens world's largest biomanufacturing line
WuXi Biologics said that its MFG5 drug-substance manufacturing facility in China has initiated good manufacturing practices-compliant operation on a 36,000-L...
Tubulis, WuXi partner to bring antibody-drug conjugates to clinical trials
Tubulis and WuXi Biologics have announced a strategic collaboration to manufacture Tubulis' next-generation antibody-drug conjugates toward investigational...
ViGeneron partners with WuXi for gene therapy manufacturing
ViGeneron and WuXi Advanced Therapies have announced the formation of a strategic partnership to accelerate the clinical development of VG901, a next-generation...
WuXi increases GMP plasmid DNA services
WuXi Advanced Therapies has expanded its cell and gene therapy platforms with capabilities to provide high-quality and cost-effective good manufacturing...

Copyright © 2021 scienceboard.net


Register below for our weekly Letter from the Editor to receive the latest Science news and insights.
Email
Connect
Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter